Research ExplorerPublicationsTreatment of relapsed and refractory multiple myeloma: recom...

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Standard

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. / Moreau, Philippe; Kumar, Shaji K; San Miguel, Jesús; Davies, Faith; Zamagni, Elena; Bahlis, Nizar; Ludwig, Heinz; Mikhael, Joseph; Terpos, Evangelos; Schjesvold, Fredrik; Martin, Thomas; Yong, Kwee; Durie, Brian G M; Facon, Thierry; Jurczyszyn, Artur; Sidana, Surbhi; Raje, Noopur; van de Donk, Niels; Lonial, Sagar; Cavo, Michele; Kristinsson, Sigurdur Y; Lentzsch, Suzanne; Hajek, Roman; Anderson, Kenneth C; João, Cristina; Einsele, Hermann; Sonneveld, Pieter; Engelhardt, Monika; Fonseca, Rafael; Vangsted, Annette; Weisel, Katja; Baz, Rachid; Hungria, Vania; Berdeja, Jesus G; Leal da Costa, Fernando; Maiolino, Angelo; Waage, Anders; Vesole, David H; Ocio, Enrique M; Quach, Hang; Driessen, Christoph; Bladé, Joan; Leleu, Xavier; Riva, Eloisa; Bergsagel, Peter Leif; Hou, Jian; Chng, Wee Joo; Mellqvist, Ulf-Henrik; Dytfeld, Dominik; Harousseau, Jean-Luc; Goldschmidt, Hartmut; Laubach, Jacob; Munshi, Nikhil C; Gay, Francesca; Beksac, Meral; Costa, Luciano J; Kaiser, Martin; Hari, Parameswaran; Boccadoro, Mario; Usmani, Saad Z; Zweegman, Sonja; Holstein, Sarah; Harrison, Simon; Nahi, Hareth; Cook, Gordon; Mateos, Maria-Victoria; Rajkumar, S Vincent; Dimopoulos, Meletios A; Richardson, Paul G.

In: LANCET ONCOL, Vol. 22, No. 3, 03.2021, p. e105-e118.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Moreau, P, Kumar, SK, San Miguel, J, Davies, F, Zamagni, E, Bahlis, N, Ludwig, H, Mikhael, J, Terpos, E, Schjesvold, F, Martin, T, Yong, K, Durie, BGM, Facon, T, Jurczyszyn, A, Sidana, S, Raje, N, van de Donk, N, Lonial, S, Cavo, M, Kristinsson, SY, Lentzsch, S, Hajek, R, Anderson, KC, João, C, Einsele, H, Sonneveld, P, Engelhardt, M, Fonseca, R, Vangsted, A, Weisel, K, Baz, R, Hungria, V, Berdeja, JG, Leal da Costa, F, Maiolino, A, Waage, A, Vesole, DH, Ocio, EM, Quach, H, Driessen, C, Bladé, J, Leleu, X, Riva, E, Bergsagel, PL, Hou, J, Chng, WJ, Mellqvist, U-H, Dytfeld, D, Harousseau, J-L, Goldschmidt, H, Laubach, J, Munshi, NC, Gay, F, Beksac, M, Costa, LJ, Kaiser, M, Hari, P, Boccadoro, M, Usmani, SZ, Zweegman, S, Holstein, S, Harrison, S, Nahi, H, Cook, G, Mateos, M-V, Rajkumar, SV, Dimopoulos, MA & Richardson, PG 2021, 'Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group', LANCET ONCOL, vol. 22, no. 3, pp. e105-e118. https://doi.org/10.1016/S1470-2045(20)30756-7

APA

Moreau, P., Kumar, S. K., San Miguel, J., Davies, F., Zamagni, E., Bahlis, N., Ludwig, H., Mikhael, J., Terpos, E., Schjesvold, F., Martin, T., Yong, K., Durie, B. G. M., Facon, T., Jurczyszyn, A., Sidana, S., Raje, N., van de Donk, N., Lonial, S., ... Richardson, P. G. (2021). Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. LANCET ONCOL, 22(3), e105-e118. https://doi.org/10.1016/S1470-2045(20)30756-7

Vancouver

Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. LANCET ONCOL. 2021 Mar;22(3):e105-e118. https://doi.org/10.1016/S1470-2045(20)30756-7

Bibtex

@article{56d049ae07f044c7bfbe35756ad61b31,
title = "Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group",
abstract = "This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.",
author = "Philippe Moreau and Kumar, {Shaji K} and {San Miguel}, Jes{\'u}s and Faith Davies and Elena Zamagni and Nizar Bahlis and Heinz Ludwig and Joseph Mikhael and Evangelos Terpos and Fredrik Schjesvold and Thomas Martin and Kwee Yong and Durie, {Brian G M} and Thierry Facon and Artur Jurczyszyn and Surbhi Sidana and Noopur Raje and {van de Donk}, Niels and Sagar Lonial and Michele Cavo and Kristinsson, {Sigurdur Y} and Suzanne Lentzsch and Roman Hajek and Anderson, {Kenneth C} and Cristina Jo{\~a}o and Hermann Einsele and Pieter Sonneveld and Monika Engelhardt and Rafael Fonseca and Annette Vangsted and Katja Weisel and Rachid Baz and Vania Hungria and Berdeja, {Jesus G} and {Leal da Costa}, Fernando and Angelo Maiolino and Anders Waage and Vesole, {David H} and Ocio, {Enrique M} and Hang Quach and Christoph Driessen and Joan Blad{\'e} and Xavier Leleu and Eloisa Riva and Bergsagel, {Peter Leif} and Jian Hou and Chng, {Wee Joo} and Ulf-Henrik Mellqvist and Dominik Dytfeld and Jean-Luc Harousseau and Hartmut Goldschmidt and Jacob Laubach and Munshi, {Nikhil C} and Francesca Gay and Meral Beksac and Costa, {Luciano J} and Martin Kaiser and Parameswaran Hari and Mario Boccadoro and Usmani, {Saad Z} and Sonja Zweegman and Sarah Holstein and Simon Harrison and Hareth Nahi and Gordon Cook and Maria-Victoria Mateos and Rajkumar, {S Vincent} and Dimopoulos, {Meletios A} and Richardson, {Paul G}",
note = "Copyright {\textcopyright} 2021 Elsevier Ltd. All rights reserved.",
year = "2021",
month = mar,
doi = "10.1016/S1470-2045(20)30756-7",
language = "English",
volume = "22",
pages = "e105--e118",
journal = "LANCET ONCOL",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "3",

}

RIS

TY - JOUR

T1 - Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

AU - Moreau, Philippe

AU - Kumar, Shaji K

AU - San Miguel, Jesús

AU - Davies, Faith

AU - Zamagni, Elena

AU - Bahlis, Nizar

AU - Ludwig, Heinz

AU - Mikhael, Joseph

AU - Terpos, Evangelos

AU - Schjesvold, Fredrik

AU - Martin, Thomas

AU - Yong, Kwee

AU - Durie, Brian G M

AU - Facon, Thierry

AU - Jurczyszyn, Artur

AU - Sidana, Surbhi

AU - Raje, Noopur

AU - van de Donk, Niels

AU - Lonial, Sagar

AU - Cavo, Michele

AU - Kristinsson, Sigurdur Y

AU - Lentzsch, Suzanne

AU - Hajek, Roman

AU - Anderson, Kenneth C

AU - João, Cristina

AU - Einsele, Hermann

AU - Sonneveld, Pieter

AU - Engelhardt, Monika

AU - Fonseca, Rafael

AU - Vangsted, Annette

AU - Weisel, Katja

AU - Baz, Rachid

AU - Hungria, Vania

AU - Berdeja, Jesus G

AU - Leal da Costa, Fernando

AU - Maiolino, Angelo

AU - Waage, Anders

AU - Vesole, David H

AU - Ocio, Enrique M

AU - Quach, Hang

AU - Driessen, Christoph

AU - Bladé, Joan

AU - Leleu, Xavier

AU - Riva, Eloisa

AU - Bergsagel, Peter Leif

AU - Hou, Jian

AU - Chng, Wee Joo

AU - Mellqvist, Ulf-Henrik

AU - Dytfeld, Dominik

AU - Harousseau, Jean-Luc

AU - Goldschmidt, Hartmut

AU - Laubach, Jacob

AU - Munshi, Nikhil C

AU - Gay, Francesca

AU - Beksac, Meral

AU - Costa, Luciano J

AU - Kaiser, Martin

AU - Hari, Parameswaran

AU - Boccadoro, Mario

AU - Usmani, Saad Z

AU - Zweegman, Sonja

AU - Holstein, Sarah

AU - Harrison, Simon

AU - Nahi, Hareth

AU - Cook, Gordon

AU - Mateos, Maria-Victoria

AU - Rajkumar, S Vincent

AU - Dimopoulos, Meletios A

AU - Richardson, Paul G

N1 - Copyright © 2021 Elsevier Ltd. All rights reserved.

PY - 2021/3

Y1 - 2021/3

N2 - This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

AB - This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

U2 - 10.1016/S1470-2045(20)30756-7

DO - 10.1016/S1470-2045(20)30756-7

M3 - SCORING: Review article

C2 - 33662288

VL - 22

SP - e105-e118

JO - LANCET ONCOL

JF - LANCET ONCOL

SN - 1470-2045

IS - 3

ER -